Research study to look at side effects during regular injection with factor VIII medicine named turoctocog alfa for a 8 weeks period

Registry ID

EUCTR2017-002281-46

Source registry

EUCTR

Phase

PHASE4

Sponsor

Novo Nordisk A/S

Last update

2026-08-16

Conditions

• Haemophilia A

Summary

To assess safety of turoctocog alfa during treatment and prophylaxis of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India

Related clinical trials

• Prevention of bleeding in haemophilia A by prophylactic treatment with Nuwiq®
• A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
• Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
• A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
• Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

View on source registry